Memphasys Limited (MEM.AX)
AUD 0.01
(0.0%)
AUD 0.01
(0.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 | 5.59 Million AUD | -23.21% |
| 2023 | 7.28 Million AUD | 12.49% |
| 2022 | 6.47 Million AUD | 8.38% |
| 2021 | 5.97 Million AUD | 287.19% |
| 2020 | 1.54 Million AUD | 101.68% |
| 2019 | 764.99 Thousand AUD | -11.62% |
| 2018 | 865.59 Thousand AUD | -88.76% |
| 2017 | 7.7 Million AUD | 34.76% |
| 2016 | 5.71 Million AUD | -6.25% |
| 2015 | 6.09 Million AUD | -24.67% |
| 2014 | 8.09 Million AUD | 21.88% |
| 2013 | 6.64 Million AUD | 51.31% |
| 2012 | 4.38 Million AUD | 22.74% |
| 2011 | 3.57 Million AUD | -26.63% |
| 2010 | 4.87 Million AUD | -20.81% |
| 2009 | 6.15 Million AUD | 55.65% |
| 2008 | 3.95 Million AUD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 FY | 5.59 Million AUD | -23.21% |
| 2024 Q2 | 6.53 Million AUD | 0.0% |
| 2024 Q4 | 5.59 Million AUD | 0.0% |
| 2023 Q2 | 6.08 Million AUD | 0.0% |
| 2023 Q4 | 7.28 Million AUD | 0.0% |
| 2023 FY | 7.28 Million AUD | 12.49% |
| 2022 Q2 | 6.13 Million AUD | 0.0% |
| 2022 Q4 | 6.47 Million AUD | 0.0% |
| 2022 FY | 6.47 Million AUD | 8.38% |
| 2021 FY | 5.97 Million AUD | 287.19% |
| 2021 Q4 | 5.97 Million AUD | 0.0% |
| 2021 Q2 | 2 Million AUD | 0.0% |
| 2020 Q2 | 1.5 Million AUD | 0.0% |
| 2020 FY | 1.54 Million AUD | 101.68% |
| 2020 Q4 | 1.54 Million AUD | 0.0% |
| 2019 FY | 764.99 Thousand AUD | -11.62% |
| 2019 Q4 | 764.99 Thousand AUD | 0.0% |
| 2019 Q2 | 1.54 Million AUD | 0.0% |
| 2018 FY | 865.59 Thousand AUD | -88.76% |
| 2018 Q4 | 865.59 Thousand AUD | 0.0% |
| 2018 Q2 | 1.42 Million AUD | 0.0% |
| 2017 Q4 | 7.7 Million AUD | 0.0% |
| 2017 FY | 7.7 Million AUD | 34.76% |
| 2017 Q2 | 6.42 Million AUD | 0.0% |
| 2016 Q2 | 7.01 Million AUD | 0.0% |
| 2016 FY | 5.71 Million AUD | -6.25% |
| 2016 Q4 | 5.71 Million AUD | 0.0% |
| 2015 Q4 | 6.09 Million AUD | 0.0% |
| 2015 Q2 | 5.16 Million AUD | 0.0% |
| 2015 FY | 6.09 Million AUD | -24.67% |
| 2014 Q2 | 12.25 Million AUD | 0.0% |
| 2014 FY | 8.09 Million AUD | 21.88% |
| 2014 Q4 | 8.09 Million AUD | 0.0% |
| 2014 Q3 | 8.09 Million AUD | -33.94% |
| 2014 Q1 | 12.25 Million AUD | 84.5% |
| 2013 Q2 | 3.55 Million AUD | 0.0% |
| 2013 Q1 | 3.55 Million AUD | -18.96% |
| 2013 Q4 | 6.64 Million AUD | 0.0% |
| 2013 FY | 6.64 Million AUD | 51.31% |
| 2013 Q3 | 6.64 Million AUD | 86.73% |
| 2012 FY | 4.38 Million AUD | 22.74% |
| 2012 Q4 | 4.38 Million AUD | 0.0% |
| 2011 Q4 | 3.57 Million AUD | 0.0% |
| 2011 FY | 3.57 Million AUD | -26.63% |
| 2010 FY | 4.87 Million AUD | -20.81% |
| 2010 Q4 | 4.87 Million AUD | 0.0% |
| 2009 Q4 | 6.15 Million AUD | 0.0% |
| 2009 FY | 6.15 Million AUD | 55.65% |
| 2008 Q4 | 3.95 Million AUD | 0.0% |
| 2008 FY | 3.95 Million AUD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| EZZ Life Science Holdings Limited | 4.22 Million AUD | -32.235% |
| Anatara Lifesciences Ltd | 306.84 Thousand AUD | -1722.522% |
| Zelira Therapeutics Limited | 9.35 Million AUD | 40.23% |
| Biome Australia Limited | 5.37 Million AUD | -4.078% |
| Patrys Limited | 691.36 Thousand AUD | -708.891% |
| Orthocell Limited | 22.08 Million AUD | 74.675% |
| Imugene Limited | 33.14 Million AUD | 83.127% |
| Noxopharm Limited | 1.28 Million AUD | -333.985% |
| PYC Therapeutics Limited | 10.18 Million AUD | 45.087% |
| Chimeric Therapeutics Limited | 12.8 Million AUD | 56.32% |
| Prescient Therapeutics Limited | 2.32 Million AUD | -140.475% |
| Proteomics International Laboratories Limited | 1.62 Million AUD | -243.951% |
| Cynata Therapeutics Limited | 1.17 Million AUD | -377.552% |
| CSL Limited | 27.88 Billion AUD | 99.98% |
| Arovella Therapeutics Limited | 2.05 Million AUD | -171.919% |
| Bio-Gene Technology Limited | 368.44 Thousand AUD | -1417.832% |
| Clinuvel Pharmaceuticals Limited | 28.11 Million AUD | 80.107% |
| Starpharma Holdings Limited | 8.69 Million AUD | 35.705% |
| Nanollose Limited | 465.64 Thousand AUD | -1101.004% |
| Invex Therapeutics Ltd | 431.63 Thousand AUD | -1195.645% |
| NeuroScientific Biopharmaceuticals Limited | 85.68 Thousand AUD | -6426.84% |
| Amplia Therapeutics Limited | 3.42 Million AUD | -63.196% |
| Botanix Pharmaceuticals Limited | 3.73 Million AUD | -49.847% |
| Island Pharmaceuticals Limited | 1.04 Million AUD | -434.838% |
| Race Oncology Limited | 1.91 Million AUD | -191.814% |
| Nyrada Inc. | 855.63 Thousand AUD | -553.597% |
| Telix Pharmaceuticals Limited | 249.39 Million AUD | 97.758% |
| Dimerix Limited | 13.89 Million AUD | 59.747% |
| PharmAust Limited | 896.6 Thousand AUD | -523.728% |
| Immutep Limited | 10.97 Million AUD | 49.066% |
| Clarity Pharmaceuticals Ltd | 8.33 Million AUD | 32.879% |
| Alterity Therapeutics Limited | 5.42 Million AUD | -3.073% |
| BTC Health Limited | 203.94 Thousand AUD | -2642.068% |
| Acrux Limited | 5.68 Million AUD | 1.664% |
| Neuren Pharmaceuticals Limited | 42.76 Million AUD | 86.922% |
| Biotron Limited | 737.5 Thousand AUD | -658.282% |
| Tissue Repair Ltd | 1.35 Million AUD | -313.974% |
| AdAlta Limited | 3.54 Million AUD | -57.863% |
| Radiopharm Theranostics Limited | 44.68 Million AUD | 87.484% |
| Hexima Limited | 248.67 Thousand AUD | -2148.921% |
| AnteoTech Limited | 4.07 Million AUD | -37.228% |
| Paradigm Biopharmaceuticals Limited | 3.58 Million AUD | -56.023% |
| Recce Pharmaceuticals Ltd | 15.89 Million AUD | 64.813% |
| Avecho Biotechnology Limited | 941.54 Thousand AUD | -493.962% |
| Actinogen Medical Limited | 1.61 Million AUD | -246.199% |
| Immuron Limited | 2.84 Million AUD | -96.879% |
| Argenica Therapeutics Limited | 2.42 Million AUD | -130.451% |